Delcath Systems Inc (DCTH)

[Rapture2020]

Revenue generating biotech business in Europe and on the cusp of FDA approval stateside for a therapy in what will eventually become a $2,500,000,000 (billion) market to treat various liver and colon cancers.

Yet circular Sam thinks the value is at subpenny because, well, that’s where he wants to buy in again.

Dude. Let’s jump into your wormhole: You pimped this stock at a present day value of $422 a share!!!

Now, you believe it’s sub-penny a share?

I’ve come across some characters in my time, sir.